Cortnee Roman
Family · Salt Lake City, UTNPI 1356585210
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Biogen at 41.5% of the total. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,216 payments — averaging $307.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$155K
- TG Therapeutics, Inc.$77K
- Amgen$45K
- E.r. Squibb & Sons, L.L.C.$29K
- AstraZeneca$23K
- EMD Serono, Inc.$10K
- plus $35K from 33 others
What the payments were for
- Consulting fees$70,52319%
- Speaking & faculty fees$209,16856%
- Travel & lodging$70,96919%
- Food & beverage$22,6476%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 275 | $155,083 |
| TG Therapeutics, Inc. | 148 | $77,211 |
| Amgen(2 entities) | 113 | $45,142 |
| E.r. Squibb & Sons, L.L.C. | 56 | $28,548 |
| AstraZeneca | 48 | $23,000 |
| EMD Serono, Inc. | 127 | $9,874 |
| UCB, Inc. | 23 | $8,626 |
| Bristol Myers Squibb | 90 | $8,606 |
| Genentech USA, Inc. | 30 | $6,495 |
| Novartis | 119 | $6,052 |
| AbbVie(2 entities) | 66 | $1,146 |
| Banner Life Sciences, LLC | 10 | $913 |
| Sanofi | 20 | $645 |
| Argenx US, Inc. | 12 | $303 |
| SK Life Science, Inc. | 13 | $293 |
| Axsome Therapeutics, Inc. | 9 | $174 |
| Janssen Scientific Affairs, LLC | 5 | $167 |
| Genentech, Inc. | 6 | $166 |
| Pfizer | 9 | $150 |
| Johnson & Johnson(2 entities) | 3 | $147 |
| Eisai Inc. | 4 | $101 |
| CSL Behring | 3 | $93 |
| Lilly USA, LLC | 5 | $90 |
| Abbott | 1 | $88 |
| ANI Pharmaceuticals, Inc. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| Mylan Specialty L.p. | 1 | $39 |
| Merz Pharmaceuticals, LLC | 1 | $32 |
| Grifols USA, LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $19 |
| Sandoz | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$373,560 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $138,699 |
| Teriflunomide | 34 | $20,304 |
| Glatiramer Acetate | 12 | $16,638 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $8,946 |
| Dalfampridine ErDalfampridine | 26 | $6,320 |
| Gabapentin | 37 | $1,948 |
| Baclofen | 53 | $1,906 |
| Modafinil | 20 | $1,072 |
| Pregabalin | 14 | $819 |
| Lamotrigine | 18 | $651 |
| Armodafinil | 11 | $543 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $491 |
| Zolpidem Tartrate | 15 | $158 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $154 |
| Sumatriptan Succinate | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $27 | $138,69920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.
Other family in Salt Lake City
- Katrina BawdenSalt Lake City$395K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Kacie Doyle-DelgadoSalt Lake City$80K
- Melonie ThompsonSalt Lake City$45K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
- Jessica ArbogastSalt Lake City$20K
- Jennifer LloydSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.